Clinical Trials
Clinical trials should be every patient's starting point when it comes to pancreatic cancer. Find out about trials that are available today, and the cutting-edge research available to patients.
149 Articles
Using Ultrasound to Enhance the Effectiveness of Chemotherapy
A clinical trial combines ultrasound with a microbubble contrast agent to make chemotherapy more effective.
Slowing the Growth of One Type of Advanced Neuroendocrine Tumor
Dr. Kelsey Klute explains the advantages of the radiopharmaceutical lutetium Lu 177 dotatate treatment for certain neuroendocrine tumors.
Leveraging Nanoparticle Technology for Paclitaxel Delivery in Pancreatic Cancer Patients
Dr. Allyson Ocean explains why nanoparticle delivery technology for getting paclitaxel to the tumor could be advantageous for patients.
For Families at Risk, Remote Education May Be Key in Improving Genetic Testing Uptake
What’s the best way to educate families at risk for pancreatic cancer about genetic testing? Dr. Sapna Syngal discusses the results of the GENERATE study.
Platform Trial Increases Efficiency in Studying Immunotherapy
Dr. Elizabeth Jaffee is betting that three types of immunotherapy will rev up the immune system and make chemotherapy more effective in a platform trial.
Chemotherapy Plus Immunotherapy Trial Shows Promise
Dr. Gulam Manji leads a clinical trial that uses two types of immunotherapy to enhance chemotherapy for pancreatic cancer patients.
New Vaccine Harnesses Power Of the Lymph Nodes
A promising new vaccine targets KRAS, the most common mutation in pancreatic cancer. Dr. Shubham Pant provides an update.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
Progress and Promise—Research in 2023
What advances were made in 2023 for pancreatic cancer treatments? Where is research headed in the coming year?
Two-Drug Combo Targets KRAS and Fights Resistance
Researcher Hervé Tiriac leads a clinical trial for a new drug combination targeting KRAS and chemotherapy resistance.